drugset / Trial / NCT00252330
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control. In addition, the tolerability and safety of SR58611A in patients with MDD will be evaluated.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-01
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | amibegron | Small molecule | 350 mg | — |